Page last updated: 2024-11-05

buthionine sulfoximine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Buthionine sulfoximine (BSO) is a potent and selective inhibitor of γ-glutamylcysteine synthetase (γ-GCS), the rate-limiting enzyme in the biosynthesis of glutathione (GSH). GSH is a major cellular antioxidant, and BSO has been extensively studied for its ability to deplete GSH levels in various tissues and cells. BSO is synthesized via a multi-step chemical process involving the reaction of L-buthionine with L-sulfoximine. It is used in research to investigate the role of GSH in various biological processes, including detoxification, cell signaling, and immune function. BSO has also been investigated as a potential therapeutic agent for conditions such as cancer, neurodegenerative diseases, and inflammatory disorders.'

Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

L-buthionine-(S,R)-sulfoximine : A 2-amino-4-(S-butylsulfonimidoyl)butanoic acid which has S-configuration. It is a inhibitor of gamma-glutamylcysteine synthetase and glutathione (GSH) biosynthesis and is capable of enhancing the apoptotic effects of several chemotherapeutic agents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID21157
CHEMBL ID1627290
CHEMBL ID1256575
CHEBI ID28714
CHEBI ID176510
SCHEMBL ID62033
MeSH IDM0028777
PubMed CID119565
CHEMBL ID261642
CHEBI ID94288
SCHEMBL ID62034
MeSH IDM0028777

Synonyms (151)

Synonym
CHEBI:28714 ,
dl-butathionine-(s,r)-sulfoximine
CHEBI:176510
2-amino-4-(s-butylsulfonimidoyl)butyric acid
NCI60_002827
NSC326231 ,
butanoic acid, 2-amino-4-(s-butylsulfonimidoyl)-
EU-0100231
dl-buthionine-(s,r)-sulfoximine
buthionine sulphoximine
butionine sulfoximine
nsc 381100
buthione sulfoximine
sulfoximine, s-(3-amino-3-carboxypropyl)-s-butyl-
2-amino-4-(s-butylsulfonimidoyl)butanoic acid
LOPAC0_000231
dl-buthionine-s,r-sulfoximine
nsc381100
buthionine-s,r-sulfoximine
buthionine sulfoxamine
71765-30-5
2-amino-4-(butylsulfonimidoyl)butanoic acid
BSPBIO_002464
nsc-381100
buthionine sulfoximine
C04543
5072-26-4
s-butyl-dl-homocysteine-[s,r]-sulfoximine
NCGC00093696-02
SPECTRUM1505108
NCGC00093696-01
dl-buthionine-[s,r]-sulfoximine
NCGC00093696-03
l-buthionine (s,r)-sulfoximine
s-butyl-dl-homocysteine (s,r)-sulfoximine
dl-buthionine-sulfoximine, >=99.0% (tlc)
NCGC00015148-03
B 2640
NCGC00015148-06
2-azaniumyl-4-(butylsulfonimidoyl)butanoate
FT-0663956
CHEMBL1627290
dl-buthionine (s,r)-sulfoximine
HMS3260P03
CHEMBL1256575
CCG-204326
NCGC00015148-05
NCGC00015148-04
unii-lw4108q0bv
lw4108q0bv ,
d,l-buthionine-(s,r)-sulfoximine
FT-0624379
FT-0627738
NCGC00015148-07
LP00231
S2433
BRD-A04020513-001-01-9
buthionine sulfoximine [mi]
buthionine sulfoximine [who-dd]
AKOS022106364
STL328818
SCHEMBL62033
2-amino-4-(butylsulfonimidoyl)butanoic acid #
KJQFBVYMGADDTQ-UHFFFAOYSA-N
tox21_500231
NCGC00260916-01
DTXSID6044434
dl-buthionine-sulfoximine
mfcd00070309
HY-106376
CS-0025687
dl-buthionine(s,r)-sulfoximine (h-dl-hcy(o,nh,bu)-oh)
2-amino-4-[butyl(imino)oxo-??-sulfanyl]butanoic acid
AS-67962
SR-01000075713-1
sr-01000075713
DB12870
BCP24029
Q5002519
BCP27775
d,l-buthionine-(s,r)-sulfoximine (butionine sulfoximine)
SDCCGSBI-0050219.P003
NCGC00015148-13
dl-buthionine-(s,r)-sulfoximine;bso
2-amino-4-(butylsulfonimidoyl)butanoicacid
SY350404
NCIMECH_000342
BSO ,
nsc-326231
83730-53-4
l-buthionine sulfoximine
EU-0100221
l-buthionine-sulfoximine, >=97% (tlc)
l-buthionine-(s,r)-sulfoximine
butanoic acid, 2-amino-4-(s-butylsulfonimidoyl)-, (2s)-
l-buthionine-(s,r)-sulphoximine
brn 2367136
nsc 326231
l-buthionine (sr)-sulfoximine
buthionine-s,r-sulfoximine, l-
LOPAC0_000221
NCGC00093690-02
NCGC00093690-01
l-buthionine-sulfoximine
2-amino-4-(s-butylsulfonimidoyl)butanoate
BUTHIONINE-SULFOXIMINE ,
B 2515
NCGC00093690-03
CHEMBL261642
buthionine sulfoxime
(2s)-2-amino-4-(butylsulfonimidoyl)butanoic acid
97590-40-4
l-buthionine(s,r)-sulfoximine
HMS3260N03
eey8dzs103 ,
buthionine sulfoximine, l-
unii-eey8dzs103
(r*,s*)-(+-)-2-amino-4-(s-butylsulfonimidoyl)butanoic acid
1-beta-dl-buthionine(s,r)sulfoximine
butanoic acid, 2-amino-4-(s-butylsulfonimidoyl)-, (r*,s*)-(+-)-
d,l-buthionine-s,r-sulfoximine
butanoic acid, 2-amino-4-((r)-s-butylsulfonimidoyl)-, (2s)-rel-
(2s)-2-amino-4-(s-butylsulfonimidoyl)butanoic acid
S9728
l-bso
LP00221
BRD-A47706533-001-01-8
SCHEMBL62034
l-buthionine-(r,s)-sulfoximine
tox21_500221
NCGC00260906-01
mfcd00067000
HY-106376A
CS-W020947
l-buthionine-sulfoximine (h-l-hcy(o,nh,bu)-oh)
AKOS027320570
CHEBI:94288
AS-69850
(2s)-2-amino-4-[butyl(imino)oxo-??-sulfanyl]butanoic acid
bdbm50487312
sr-01000075712
SR-01000075712-1
DTXSID70894150
Q27166100
bso (l-buthionine-(s,r)-sulfoximine)
SDCCGSBI-0050209.P002
NCGC00093690-11
nsc-801426
nsc801426
A857917
l-butionine sulfoximine

Research Excerpts

Overview

Buthionine sulfoximine (BSO) is a synthetic amino acid that blocks the biosynthesis of reduced glutathione (GSH) BSO is an adjuvant drug reported to increase the sensitivity of cancer cells to neoplastic agents.

ExcerptReferenceRelevance
"Buthionine sulfoximine (BSO) is a specific inhibitor of γ-glutamylcysteine synthetase, thus blocking the synthesis of glutathione (GSH). "( Buthionine sulfoximine diverts the melanogenesis pathway toward the production of more soluble and degradable pigments.
Alonso-Alvarez, C; Galván, I; Solano, F; Wakamatsu, K, 2014
)
3.29
"Buthionine sulfoximine (BSO) is a synthetic amino acid that blocks the biosynthesis of reduced glutathione (GSH), an endogenous antioxidant cellular component present in tumor cells. "( Buthionine sulfoximine and chemoresistance in cancer treatments: a systematic review with meta-analysis of preclinical studies.
Barros Ibiapina, A; Carneiro da Silva, FC; de Castro E Sousa, JM; Dos Reis Oliveira, C; Ferreira, PMP; Pereira, JC; Roseno Martins, IR, 2023
)
3.8
"l-Buthionine sulfoximine (l-BSO) is an adjuvant drug that is reported to increase the sensitivity of cancer cells to neoplastic agents. "( l-Buthionine Sulfoximine Detection and Quantification in Polyurea Dendrimer Nanoformulations.
Bonifácio, VDB; Mota, P; Pires, RF; Serpa, J, 2019
)
1.96
"L-buthionine sulfoximine (BSO) is an inhibitor of GSH synthesis."( Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine.
Han, YH; Kim, SH; Kim, SZ; Park, WH, 2008
)
1.13
"Buthionine sulfoximine (BSO) is a well-known inhibitor of glutathione synthesis, producing slow glutathione (GSH) depletion and oxidative stress; some "responder" cells avoid BSO-induced death by trans-activating the prosurvival protein Bcl-2. "( Oxidative, multistep activation of the noncanonical NF-kappaB pathway via disulfide Bcl-3/p50 complex.
Cristofanon, S; Dicato, M; Diederich, M; Ghibelli, L; Morceau, F; Scovassi, AI, 2009
)
1.8
"L-Buthionine sulfoximine (BSO) is a potent inhibitor of glutathione biosynthesis and studies have shown that it is capable of enhancing the apoptotic effects of several chemotherapeutic agents. "( Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer.
Jordan, VC; Kim, H; Lewis-Wambi, JS; Swaby, R, 2009
)
1.43
"Buthionine sulfoximine (BSO) is a synthetic amino acid that irreversibly inhibits an enzyme, gamma-glutamylcysteine synthetase (gamma-GCS), which is a critical step in glutathione biosynthesis. "( Markedly decreased expression of glutathione S-transferase pi gene in human cancer cell lines resistant to buthionine sulfoximine, an inhibitor of cellular glutathione synthesis.
Cowan, KH; Kohno, K; Kuwano, M; Morrow, CS; Ono, M; Wada, M; Yokomizo, A, 1995
)
1.95
"Buthionine sulfoximine (BSO) is an inhibitor of glutathione synthesis that can deplete intracellular glutathione and reverse resistance to platinating and alkylating agents in vitro and in vivo. "( Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
Brennan, JM; Hamilton, TC; Lacreta, FP; O'Dwyer, PJ; Ozols, RF,
)
1.57
"Buthionine sulfoximine (BSO) is a synthetic amino acid that irreversibly inhibits glutathione biosynthesis and deranges reduced glutathione (GSH) metabolism in liver cells. "( Cellular balance of glutathione levels through the expression of gamma-glutamylcysteine synthetase and glutathione thiol transferase genes in human hepatic cells resistant to a glutathione poison.
Kohno, K; Kondo, T; Kuwano, M; Nishio, K; Nomoto, M; Saijo, N; Tanaka, T; Uchiumi, T, 1999
)
1.75
"Buthionine sulfoximine (BSO) is an inhibitor of glutathione biosynthesis and may increase cytotoxicities of alkylating agents, including melphalan and cisplatin, and radiation in sensitive and resistant cell lines."( Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.
Hong, YS; Kang, JH; Kim, DJ; Kim, HK; Lee, KS; Moon, HS; Park, JG, 1992
)
1.39
"Buthionine sulfoximine (BSO) is an inhibitor of glutathione synthesis and can be used to potentiate the effects of chemotherapeutic alkylating agents and radiotherapy. "( Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas.
Bigner, DD; Fekete, I; Friedman, HS; Griffith, OW; Groothuis, DR; Schlageter, KE, 1990
)
2.16

Effects

ExcerptReferenceRelevance
"Buthionine sulfoximine (BSO) has been used to deplete glutathione (GSH) in V79-379A cells in vitro, and the effect on the efficiency of oxygen and misonidazole (MISO) as radiosensitizers has been determined. "( Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro.
Denekamp, J; Minchinton, AI; Shrieve, DC, 1985
)
1.99

Actions

Buthionine sulfoximine (BSO) is used to inactivate glutathione synthesis. Small increments of acetaminophen are given intravenously to maintain the plasma level at approximately 200 micrograms/ml for 20 hr.

ExcerptReferenceRelevance
"Buthionine sulfoximine (BSO) to inhibit GSH synthesis and celecoxib (CXB) to down-regulate P-gp expression were co-loaded in polymer/inorganic hybrid nanoparticles to form buthionine sulfoximine/celecoxib@biotin-heparin/heparin/calcium carbonate/calcium phosphate nanoparticles (BSO/CXB@BNP)."( Co-delivery of multiple drug resistance inhibitors by polymer/inorganic hybrid nanoparticles to effectively reverse cancer drug resistance.
Cheng, SX; Gong, MQ; Liu, BY; Wu, C; Zhuo, RX, 2017
)
1.18
"Buthionine sulfoximine is used to inactivate glutathione synthesis, and small increments of acetaminophen are given intravenously to maintain the plasma level at approximately 200 micrograms/ml for 20 hr."( An improved model of acetaminophen-induced fulminant hepatic failure in dogs.
Chong, MG; He, DE; Kelly, JH; Koussayer, T; Shang, TA; Sussman, NL; Whisennand, HH, 1992
)
1

Treatment

Buthionine sulfoximine (BSO) treatment reduced diaphragm GSH content and the ratio of GSH to glutathione disulfide by 91% and 71%, respectively, compared with controls (CTL) (n = 10) BSO pretreatment also increased the number of camptothecin-induced DNA-protein crosslinks, indicating that GSH affects the mechanism of action.

ExcerptReferenceRelevance
"Buthionine sulfoximine pretreatment also increased the number of camptothecin-induced DNA-protein crosslinks, indicating that GSH affects the mechanism of action of camptothecin."( Dual role of glutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex.
Adams, DJ; Colvin, OM; Flowers, JL; Gamcsik, MP; Kasibhatla, MS; Kohlhagen, G; Manikumar, G; Pommier, Y; Wall, ME; Wani, M, 2001
)
1.03
"Buthionine sulfoximine treatment resulted in a 24% reduction in canine atrial glutathione content, a reduction in atrial contractility, and an attenuation of I(Ca,L) in the canine atrial myocytes."( Atrial glutathione content, calcium current, and contractility.
Bauer, JA; Carnes, CA; Chung, MK; Fearon, IM; Gillinov, AM; Haase, H; Hamlin, RL; Janssen, PM; Nakayama, H; Nakayama, T; Ruehr, ML; Van Wagoner, DR, 2007
)
1.06
"Buthionine sulfoximine (BSO) treatment (n = 10) for 10 days (20 mM in drinking water) reduced (P < 0.05) diaphragm GSH content (nmol/mg protein) and the ratio of GSH to glutathione disulfide (GSH/GSSG) by 91% and 71%, respectively, compared with controls (CTL) (n = 10)."( Effects of buthionine sulfoximine treatment on diaphragm contractility and SR Ca2+ pump function in rats.
Denniss, SG; Ford, RJ; Graham, DA; Rush, JW; Tsuchiya, SC; Tupling, AR; Vigna, C, 2007
)
1.45
"Buthionine sulfoximine (BSO) pretreatment resulted in a further increase of binding either to PH or FC."( In vivo production of different chloroform metabolites: effect of phenobarbital and buthionine sulfoximine pretreatment.
Gemma, S; Sbraccia, M; Testai, E; Vittozzi, L, 1994
)
1.23
"Buthionine sulfoximine (BSO) pretreatment significantly reduced cardiac glutathione in sham pigs from 394 +/- 46 to 199 +/- 26 micrograms/g; and in endotoxemic pigs, BSO pretreatment significantly reduced cardiac glutathione to 106 +/- 18 micrograms/g."( Deleterious effects of buthionine sulfoximine on cardiac function during continuous endotoxemia.
Andrejuk, T; Dziuban, SW; Goldfarb, RD; Lee, KJ, 1995
)
1.32
"L-Buthionine sulfoximine (BSO) treatment (concentration, 20 microM, applied for 17 hours) resulted in 77% and 63% GSH depletion compared with the untreated RR and RS cells, respectively."( Effect of L-buthionine sulfoximine on the radiation response of human renal carcinoma cell lines.
al-Nabulsi, I; Belldegrun, A; Friedman, N; Kasid, U; Leung, SW; Mitchell, JB; Newsome, J, 1993
)
1.22
"Buthionine sulfoximine pretreatment depleted liver glutathione concentrations by 85% at the time of halothane exposure, without affecting the degree of halothane biotransformation or causing hepatic injury."( Glutathione depletion enhances subanesthetic halothane hepatotoxicity in guinea pigs.
Gandolfi, AJ; Hall, PM; Lind, RC, 1992
)
1
"Buthionine sulfoximine (BSO) treatment significantly reduced testicular epididymal and vas deferens glutathione (GSH) levels in rats. "( Depression of glutathione in male reproductive tissues and potentiation of EMS-induced germ cell mutagenesis by L-buthionine sulfoximine.
Bishop, JB; Harbison, RD; Teaf, CM, 1987
)
1.93
"Pretreatment with buthionine sulfoximine (BSO), an inhibitor of GSH synthesis, enhanced MT synthesis itself as well as that induced by TSO and cis-stilbene oxide (CSO)."( Induction of metallothionein synthesis by glutathione depletion after trans- and cis-stilbene oxide administration in rats.
Kuroiwa, Y; Oguro, T; Sasaki, M; Sato, M; Yoshida, T, 1995
)
0.61
"Pretreatment with buthionine sulfoximine for 17 h exaggerated the negative chronotropic effects of CHPO: the time elapsed to 50% of baseline contraction frequency fell from 5.7 +/- 1.4 min without buthionine sulfoximine to 3.7 +/- 0.4 min after pretreatment with buthionine sulfoximine (P < 0.02)."( Buthionine sulfoximine reduces the protective capacity of myocytes to withstand peroxide-derived free radical attack.
Hollaar, L; Le, CT; van der Laarse, A; van der Valk, EJ, 1993
)
2.05
"Pretreatment with buthionine sulfoximine resulted in higher levels of albumin adduct but in no alteration of hemoglobin adduct levels in comparison with control."( Reactive naphthalene metabolite binding to hemoglobin and albumin.
Buckpitt, A; Cho, M; Hammock, B; Jedrychowski, R, 1994
)
0.61
"Treatment with buthionine sulfoximine, a specific inhibitor of GSH synthesis sensitized both cell lines to ADR only when the cellular GSH levels were depleted to about 5% of control."( Decreased sensitivity to adriamycin in cadmium-resistant human lung carcinoma A549 cells.
Alexander, JM; Hatcher, EL; Kang, YJ, 1997
)
0.64
"Pretreatment with buthionine sulfoximine increased the amount of immunostaining."( In vivo formation and localization of 1,1-dichloroethylene epoxide in murine liver: identification of its glutathione conjugate 2-S-glutathionyl acetate.
Forkert, PG, 1999
)
0.63
"Pretreatment with buthionine sulfoximine, which inhibits glutathione synthesis, abolished the beneficial effect of S-adenosylmethionine on survival and plasma glutathione level."( S-adenosylmethionine protects against acetaminophen hepatotoxicity in two mouse models.
Bray, GP; Tredger, JM; Williams, R, 1992
)
0.61
"Pretreatment of buthionine sulfoximine (500 mg/kg, i.p., BSO), a potent glutathione-depleting agent, markedly increased the lethality and nephrotoxicity of cisplatin. "( Enhancement of cisplatin toxicity by buthionine sulfoximine, a glutathione-depleting agent, in mice.
Ishikawa, M; Sasaki, K; Takayanagi, Y, 1990
)
0.9
"Pretreatment of buthionine sulfoximine (500 mg/kg, i.p., BSO), a potent glutathione-depleting agent, markedly increased the lethality and nephrotoxicity of cisplatin. "( The deleterious effect of buthionine sulfoximine, a glutathione-depleting agent, on the cisplatin toxicity in mice.
Ishikawa, M; Sasaki, K; Takayanagi, Y, 1990
)
0.93
"Mice treated with buthionine sulfoximine, an inhibitor of glutathione synthesis, showed striking alterations of morphology of lung type 2 cell lamellar bodies (swelling and disintegration) and mitochondria (degeneration) and of lung capillary endothelial cells (mitochondrial swelling). "( Glutathione metabolism in the lung: inhibition of its synthesis leads to lamellar body and mitochondrial defects.
Frayer, W; Jain, A; Mårtensson, J; Meister, A, 1989
)
0.61
"Mice treated with buthionine sulfoximine [an effective irreversible inhibitor of gamma-glutamylcysteine synthetase (EC 6.3.2.2) that decreases cellular levels of glutathione markedly] were sensitized to the toxic effects of CdCl2."( Glutathione, a first line of defense against cadmium toxicity.
Anderson, ME; Meister, A; Singhal, RK, 1987
)
0.6
"Pretreatment with buthionine sulfoximine (BSO; 900 mg/kg) induced the elevation of serum GOT and GPT activities in a non-toxic dose of butylated hydroxytoluene (BHT; 250-500 mg/kg) in rats. "( Effects of buthionine sulfoximine and cysteine on the hepatotoxicity of butylated hydroxytoluene in rats.
Nakagawa, Y, 1987
)
1

Toxicity

ExcerptReferenceRelevance
" Comparison of the tested compounds showed that the structural requirements for toxic potency was a phenolic ring having an allyl substituent at the 4-position."( Hepatotoxicity of eugenol and related compounds in mice depleted of glutathione: structural requirements for toxic potency.
Mizutani, T; Nomura, H; Satoh, K, 1991
)
0.28
" Intraperitoneal injection of Cr(VI) did not inhibit hepatic glutathione reductase activity, even at toxic doses."( Possible role of glutathione in chromium(VI) metabolism and toxicity in rats.
Standeven, AM; Wetterhahn, KE, 1991
)
0.28
" Sera from both rats and monkeys following gavage with acetaminophen were also toxic to cultured embryos."( Acetaminophen toxicity to cultured rat embryos.
Bruno, M; Gamache, P; Hinson, JA; Khairallah, E; Klein, NW; Weeks, BS, 1990
)
0.28
"The rationale for melanoma specific dihydroxybenzene containing antitumor agents is based in part upon the ability of the enzyme tyrosinase to oxidize these pro drugs to toxic intermediates."( Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells.
Fitzgerald, GB; Prezioso, JA; Wick, MM,
)
0.36
" These data suggest that the nephrotoxicity of PAP may be due in part to the formation of a proximate toxic metabolite in the liver which is excreted in the bile, subsequently reabsorbed and transported via the systemic circulation to the kidney where the toxic effects occur."( Effects of biliary cannulation and buthionine sulphoximine pretreatment on the nephrotoxicity of para-aminophenol in the Fischer 344 rat.
Bonner, FW; Eason, CT; Gartland, KP; Nicholson, JK, 1990
)
0.28
" That administration of glutathione has a protective effect on cisplatin toxicity suggests that the toxic effects of cisplatin may be exerted both intracellularly and extracellularly, and that extracellular glutathione (or its degradation products) may form a complex with cisplatin extracellularly."( Protection against cisplatin toxicity by administration of glutathione ester.
Anderson, ME; Meister, A; Naganuma, A, 1990
)
0.28
" The production of a toxic metabolite in the livers of glutathione-depleted mice that is circulated to susceptible renal cells may be the mechanism of this interesting organ-selective shift in toxicity of 3MI."( Organ-selective switching of 3-methylindole toxicity by glutathione depletion.
Kuntz, DJ; McGill, LD; Yost, GS, 1990
)
0.28
" Since diet and many drugs (including cyclophosphamide itself) are known to affect glutathione levels, the present studies suggest that cardiac and skeletal muscle glutathione content is likely to be a clinically significant determinant of the frequency and severity of the adverse drug interactions and systemic toxicity sometimes observed during cyclophosphamide therapy."( Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity.
Aisaka, K; Bossen, EH; Colvin, OM; Friedman, HS; Gross, SS; Hilton, J; Levi, R; Popp, J; Powell, JB; Reimer, KA, 1990
)
0.28
" Administration of a toxic dose of precocene II (175 mg/kg) to male Sprague-Dawley rats rapidly depleted hepatic GSH, produced histopathological changes in the liver, and induced increases in serum aminotransferase activity."( Alteration of precocene II-induced hepatotoxicity by modulation of hepatic glutathione levels.
Duddy, SK; Hsia, MT, 1989
)
0.28
" INO was very toxic towards HT-29 cells and was equally toxic under aerobic and hypoxic conditions."( Cytotoxicity and glutathione depletion by 1-methyl-2-nitrosoimidazole in human colon cancer cells.
Gipp, JJ; McClelland, RA; Mulcahy, RT; Panicucci, R; Ublacker, GA, 1989
)
0.28
"2) that decreases cellular levels of glutathione markedly] were sensitized to the toxic effects of CdCl2."( Glutathione, a first line of defense against cadmium toxicity.
Anderson, ME; Meister, A; Singhal, RK, 1987
)
0.27
" Basic amino acids (except histidine) were less effective in protecting embryos: Glutamine and lysine reduced the toxic effect only slightly, and arginine had no effect."( Enhancement of methylmercury toxicity by L-cystine in cultured mouse blastocysts.
Matsumoto, N; Spindle, A,
)
0.13
" Thus the toxic effects after acute GSH depletion to approximately equal to 5% of control by BSO plus dimethylfumarate (DMF) were evaluated in these same 66 cells to determine if this anti-proliferative effect could be minimized."( Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
Biaglow, JE; Dethlefsen, LA; Lehman, CM; Peck, VM, 1988
)
0.53
" Yet neither substance protected mice from the toxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons, as shown by marked depletion of striatal dopamine content when animals were sacrificed."( Manipulation of glutathione contents fails to alter dopaminergic nigrostriatal neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
Jones, K; Perry, TL; Wright, JM; Yong, VW, 1986
)
0.27
" Although these derivatives did not display selective toxicity toward the hypoxic cells, they were significantly more toxic than 6-TC to this cell line at 500 microM after a 2-h exposure."( Modification of antitumor disulfide cytotoxicity by glutathione depletion in murine cells.
Kirkpatrick, DL, 1987
)
0.27
" In contrast, pretreatment with cysteine (100-200 mg/kg) inhibited the elevation of serum enzyme activities at a toxic dose of BHT (1000 mg/kg)."( Effects of buthionine sulfoximine and cysteine on the hepatotoxicity of butylated hydroxytoluene in rats.
Nakagawa, Y, 1987
)
0.66
"Previous data have demonstrated that methyl chloride (MeCl) is toxic to B6C3F1 mice under both acute and chronic exposure conditions, and that conjugation of MeCl with glutathione (GSH) is a key step in the metabolism of MeCl."( Inhibition of the acute toxicity of methyl chloride in male B6C3F1 mice by glutathione depletion.
Bus, JS; Chellman, GJ; Norton, RM; White, RD, 1986
)
0.27
" These structural requirements essentially are the same as those for the toxic potency in the lung (T."( Hepatotoxicity of butylated hydroxytoluene and its analogs in mice depleted of hepatic glutathione.
Fujita, S; Mizutani, T; Nakanishi, K; Nomura, H, 1987
)
0.27
" The mechanisms responsible for the disparate toxic outcomes for these closely related structural isomers are not fully understood."( Naphthylisothiocyanate disposition in bile and its relationship to liver glutathione and toxicity.
Jean, PA; Roth, RA, 1995
)
0.29
" Studies have shown that the formation of toxic metabolites can result from glutathione (GSH) conjugation of toxicants in the liver."( Profile of procarbazine-induced embryotoxicity in an embryo hepatocyte co-culture system and after in utero glutathione depletion.
Andrews, JE; Ebron-McCoy, MT; Kavlock, RJ; Nichols, HP, 1995
)
0.29
" Two groups could be distinguished: PMA, EMT and MMC are one order of magnitude more toxic than MC, MN and MA."( Cytotoxicity of mercury compounds in LLC-PK1, MDCK and human proximal tubular cells.
Bohets, HH; D'Haese, PC; De Broe, ME; Dierickx, PJ; Nouwen, EJ; Van der Biest, I; Van Landeghem, GF; Van Thielen, MN, 1995
)
0.29
" Among related amino acids, DL-alpha-aminoadipic acid (DL-alpha-AAA), which is well known as a selective gliotoxin in the retina, is also toxic to these cells."( Cystine/glutamate antiporter expression in retinal Müller glial cells: implications for DL-alpha-aminoadipate toxicity.
Ishita, S; Kato, S; Mawatari, K; Sugawara, K, 1993
)
0.29
" These results suggest that acrolein and 4HPC are equipotent cytotoxins and that a transient depletion in GSH accompanies this toxic effect in cardiac myocytes."( Effect of sulfhydryl compounds and glutathione depletion on rat heart myocyte toxicity induced by 4-hydroperoxycyclophosphamide and acrolein in vitro.
Dorr, RT; Lagel, K, 1994
)
0.29
" Hepa 1c1c-9 cells were exposed to varying concentrations of several reactive metabolites implicated in adverse drug reactions and the toxicity of the compounds assessed using applied fluorescence technology."( A comparative study of the toxicity of chemically reactive xenobiotics towards adherent cell cultures: selective attenuation of menadione toxicity by buthionine sulphoximine pretreatment.
Leeder, JS; Riley, RJ; Spielberg, SP, 1993
)
0.29
"Glutathione (GSH) and glutathione S-transferases (GSTs) play an important role in the protection of cells against toxic effects of many electrophilic drugs and chemicals."( Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen, G; Waxman, DJ, 1994
)
0.29
" The toxic effects, GSH depletion and radiosensitivity of BSO on retinoblastoma cells are reported in this paper."( The toxic effects, GSH depletion and radiosensitivity by BSO on retinoblastoma.
Ding, L; Jin, Y; Ni, C; Wang, W; Yi, X, 1994
)
0.29
" Precocene II was also toxic to 72-h cultures, although the effect of the serum-free medium was attenuated."( Toxicity of precocene II in rat hepatocyte cultures: effects of serum and culture time.
Fry, JR; Hammond, AH, 1994
)
0.29
" We have investigated whether these toxic effects of arsenite and the cellular arsenic content are also modulated by the intracellular GSH."( Glutathione as a cellular defence against arsenite toxicity in cultured Chinese hamster ovary cells.
Huang, CF; Huang, H; Jan, KY; Jinn, CM; Wu, DR, 1993
)
0.29
" While exogenous PpIX was more toxic than hemin in both cell lines, this toxicity was not due to iron depletion following intracellular heme formation since ferric citrate did not reverse PpIX toxicity."( Hemin toxicity in a human epithelioid sarcoma cell line.
Braverman, S; Helson, C; Helson, L,
)
0.13
" Azathioprine and monocrotaline were found to be selectively more toxic to SEC than to hepatocytes."( Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease.
DeLeve, LD; Kaplowitz, N; Kuhlenkamp, JF; Wang, X, 1996
)
0.29
" These findings suggest that the tissues or cells of low GSH concentration are highly vulnerable to PQ toxicity and GSH may play a major role in diminishing the toxic action of PQ exerted through oxidative stress."( Enhancement of paraquat toxicity by glutathione depletion in mice in vivo and in vitro.
Imura, N; Naganuma, A; Nakagawa, I; Suzuki, M, 1995
)
0.29
" However, the combination of BSO with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in preweanling mice and the combination of nigral injections of BSO with intrastriatal injections of MPP+ (1-methyl-4-phenylpyridinium), the active metabolite of MPTP in adult rats, potentiated the toxic effects of MPTP and MPP+ on nigral neurones."( Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones.
Dringen, R; Eblen, F; Klockgether, T; Löschmann, PA; Schmid, A; Schulz, JB; Turski, L; Wüllner, U, 1996
)
0.29
" These results demonstrate that (a) reduction in the availability of glucose and intracellular glutathione renders the cells more vulnerable to the cytotoxic effects of NO donors, (b) in this model of cytotoxicity, long-lived NO donors were more cytotoxic than short-lived NO donors, (c) the differential effects of N-acetylcysteine on S-nitroso-N-acetylpenicillamine-induced and bacterial lipopolysaccharide-mediated cytotoxicity support the existence of other toxic species different from NO or NO-related compounds with a potent cytotoxic activity in immunostimulated macrophages, and (d) other non-protein thiols like N-acetylcysteine may substitute for glutathione as a major component of the cellular antioxidant defense system."( The protective role of thiols against nitric oxide-mediated cytotoxicity in murine macrophage J774 cells.
Herman, AG; Matthys, KE; Zamora, R, 1997
)
0.3
" DL-Buthionine-[S,R]-Sulfoximine (BSO) and Diethyl maleate (DEM) were used to potentiate the toxic effect of the bipyridyl."( Biochemical studies on the toxicity of 1, 1'-dimethyl-4, 4'-bipyridylium dichloride in the rat.
Nwabisi, VC; Nwanze, EA, 1997
)
0.3
"Cadmium (Cd) is a highly toxic metal and a known carcinogen."( Effects of glutathione depletion on cadmium-induced metallothionein synthesis, cytotoxicity, and proto-oncogene expression in cultured rat myoblasts.
Hochadel, JF; Shimizu, M; Waalkes, MP, 1997
)
0.3
" The toxic process might also be mediated by glutathione (GSH) conjugates of ADCP, as suggested for the mechanism of 4-aminophenol nephrotoxicity."( 4-Amino-2,6-dichlorophenol nephrotoxicity in the Fischer 344 rat: protection by ascorbic acid, AT-125, and aminooxyacetic acid.
Anestis, DK; Ball, JG; Brown, PI; Hong, SK; Rankin, GO; Valentovic, MA, 1997
)
0.3
" These results document the ability of rat P450 2E1 to metabolize NDMA to toxic reactive intermediates and demonstrate that this cell line provides a useful model for studying the mechanisms of metabolism-mediated toxicity and carcinogenesis."( Heterologous expression of rat P450 2E1 in a mammalian cell line: in situ metabolism and cytotoxicity of N-nitrosodimethylamine.
Hollenberg, PF; Lin, HL; Roberts, ES, 1998
)
0.3
" However, under aerobic conditions, AS was more toxic than under hypoxic conditions, suggesting that oxygen dramatically enhanced AS-mediated cytotoxicity."( The cytotoxicity of nitroxyl: possible implications for the pathophysiological role of NO.
Chistodoulou, D; Cook, JA; DeGraff, WG; Feelisch, M; Fukuto, J; Gamson, J; Grisham, MB; Jourd'heuil, D; Kim, S; Krishna, M; Mitchell, JB; Vodovotz, Y; Wink, DA, 1998
)
0.3
"The ability of allylamine (AA) administration to produce vascular lesions resembling atherosclerotic disease in animals, has been linked to metabolism of AA to the toxic aldehyde acrolein (ACR) by a semicarbazide-sensitive amine oxidase (SSAO) found in plasma and in vascular smooth muscle."( [Effect of activity of semicarbazide-sensitive aminooxidases and cellular glutathione on the cytotoxic effect of allylamine, acrolein, and formaldehyde in human cultured endothelial cells].
Lyles, GA; Pino, R,
)
0.13
" Nevertheless, toxic effects of CDDP as gauged by body weight loss or survival varied significantly according to CDDP dosing time."( Pharmacological modulation of cisplatin toxicity rhythms with buthionine sulfoximine in mice bearing pancreatic adenocarcinoma (PO3).
Filipski, E; Lévi, F; Li, XM, 1998
)
0.54
" Despite these differences, 1-OHP remained least toxic at 16 HALO, near the middle of the dark span, which corresponds to maximum activity in the circadian rest/activity cycle."( Modulation of nonprotein sulphydryl compounds rhythm with buthionine sulphoximine: relationship with oxaliplatin toxicity in mice.
Filipski, E; Lemaigre, G; Lévi, F; Li, XM; Metzger, G, 1998
)
0.3
" A primary function of GSH is to prevent the toxic interaction between free radicals and reactive transition metals such as copper (Cu)."( Exacerbation of copper toxicity in primary neuronal cultures depleted of cellular glutathione.
Beyreuther, K; Bush, AI; Cappai, R; Masters, CL; White, AR, 1999
)
0.3
"Altered glial function in the substantia nigra in Parkinson's disease may lead to the release of toxic substances that cause dopaminergic cell death or increase neuronal vulnerability to neurotoxins."( Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures.
Jenner, P; McNaught, KS, 1999
)
0.3
" L-HCA induced a concentration-dependent neurotoxic effect, estimated by cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) reduction, in primary neurons, but was significantly more toxic for hippocampal (EC(50)=197 microM) compared with cortical neurons (EC(50)=1016 microM) whereas D-HCA demonstrated only moderate (<20%) toxicity."( Inhibition of L-homocysteic acid and buthionine sulphoximine-mediated neurotoxicity in rat embryonic neuronal cultures with alpha-lipoic acid enantiomers.
Cuisinier, C; Jones, C; Lestage, P; Lockhart, B; Peyroulan, D; Villain, N, 2000
)
0.31
" Similarly, ring fusion of a benzene nucleus to the C-4,5 double bond, forming 2-mercapto-1-methylbenzimidazole, abolished the toxic potency."( Evidence for the involvement of N-methylthiourea, a ring cleavage metabolite, in the hepatotoxicity of methimazole in glutathione-depleted mice: structure-toxicity and metabolic studies.
Kawazoe, S; Mizutani, T; Murakami, M; Shirai, M; Yoshida, K, 2000
)
0.31
" HC alone was slightly toxic to HepG2 cells."( Enhanced hydroxychavicol-induced cytotoxic effects in glutathione-depleted HepG2 cells.
Chen, CL; Chi, CW; Liu, TY, 2000
)
0.31
"4-Hydroxynonenal (4HNE) is the most prevalent toxic lipid peroxidation product formed during oxidative stress."( Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal.
de Vries, EE; Hooiveld, GJ; Jansen, PL; Krikken, I; Müller, M; Renes, J, 2000
)
0.31
", 1-100 nM, of 1,25-(OH)(2)D(3) protect cultured dopaminergic neurons against this toxicity, although higher concentrations of this active form of vitamin D have been found to enhance the toxic effect."( Effect of 1,25-dihydroxyvitamin D(3) on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L-buthionine sulfoximine and 1-methyl-4-phenylpyridine.
Kikuchi, S; Moriwaka, F; Sasaki, H; Shinpo, K; Tashiro, K, 2000
)
0.51
"In a previous work, it was shown that in cells after a decrease of cellular glutathione content, toxic zinc effects, such as protein synthesis inhibition or GSSG (glutathione, oxidized form) increases, were enhanced."( Zinc toxicity in various lung cell lines is mediated by glutathione and GSSG reductase activity.
Fichtl, B; Mückter, H; Walther, S; Walther, UI; Wilhelm, B, 2000
)
0.31
" Our results suggest that some cells may have mechanisms to protect themselves from ouabain toxicity and that MRP1 may have a role in controlling the toxic effects of ouabain."( Reduced glutathione protect cells from ouabain toxicity.
Affonso-Mitidieri, O; Capella, LS; Capella, MA; Gefé, M; Lopes, AG; Morales, MM; Rumjanek, VM; Silva, EF, 2001
)
0.31
" Although HECs are reliable constituents of powered propellant systems, they constitute an important class of toxic agents to which military and civilian personnel can be exposed."( In vitro toxicity assessment of a new series of high energy compounds.
Frazier, JM; Hussain, SM, 2001
)
0.31
"The toxic effect of thiram, a widely used dithiocarbamate fungicide, was investigated in cultured human skin fibroblasts."( Thiram-induced cytotoxicity is accompanied by a rapid and drastic oxidation of reduced glutathione with consecutive lipid peroxidation and cell death.
Boget, S; Cereser, C; Parvaz, P; Revol, A, 2001
)
0.31
" Since the cytotoxic effect of OTC is more in glutathione depleted cells, the concentration of OTC may be reduced to get an antitumour effect in GSH-depleted cells and thus minimizes its toxic side effect."( Antiproliferative and cytotoxic effect of a novel organotin compound on mammalian cells both in vitro and in vivo.
Basu Baul, TS; Chatterjee, A; Syng-ai, C, 2002
)
0.31
" A relationship between exposure to busulphan, expressed as an area under the plasma concentration time curve (AUC), and effect and/or adverse effects, such as veno-occlusive disease (VOD), was reported."( The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo.
Alsadi, S; Edgren, M; Hägglund, H; Hassan, M; Hassan, Z; Hellström-Lindberg, E, 2002
)
0.31
"Antioxidant drugs have been reported to protect pancreatic islets from the adverse effects of chronic exposure to supraphysiological glucose concentrations."( A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity.
Harmon, J; Robertson, RP; Tanaka, Y; Tran, PO, 2002
)
0.31
" Aberrant copper metabolism is also implicated in neurodegeneration and may result in the generation of toxic free radicals."( Neurotoxicity from glutathione depletion is dependent on extracellular trace copper.
Cappai, R; White, AR, 2003
)
0.32
"Experiments have shown that 1,4,7,10,13,16-hexathiacyclooctadecane (L3) increased the Cu2+ toxicity on HepG2 cells, whereas the combination Zn(2+)/L3 was less toxic relative to the metal control."( The role of oxidative stress on the effect of 1,4,7,10,13,16-hexathiacyclooctadecane on copper and zinc toxicity in HepG2 cells.
Bolle, F; Dierickx, PJ; Elskens, M; Smet, PW, 2003
)
0.32
" HepG2 cells over-expressing CYP2E1 (E47 cells) were treated with arachidonic acid (AA) plus iron, agents important in development of alcoholic liver injury and which are toxic to E47 cells by a mechanism dependent on CYP2E1, oxidative stress, and lipid peroxidation."( Proteasome inhibition potentiates CYP2E1-mediated toxicity in HepG2 cells.
Cederbaum, AI; Pérez, MJ, 2003
)
0.32
" In contrast, PIH was inactive, while SIH was equally toxic toward control and EPA-loaded cells, without causing lipid peroxidation, indicating a much smaller contribution of oxidative stress to the mechanism of toxicity of these analogs."( Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs.
Buss, JL; Neuzil, J; Ponka, P, 2004
)
0.32
" Exogenous AA is toxic to GSH-depleted cells."( Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites.
Cheong, J; Jnobaptiste, R; Kramer, BC; Mytilineou, C; Olanow, CW; Robakis, T; Yabut, JA, 2004
)
0.32
" Methanol is teratogenic in rodents and, although the exact toxic species is not known, teratogenesis may result from the enzymatic biotransformation of H3COH to formaldehyde (CH2O) and formic acid causing increased biological reactivity and toxicity."( Glutathione depletion modulates methanol, formaldehyde and formate toxicity in cultured rat conceptuses.
Dixon, M; Hansen, JM; Harris, C, 2004
)
0.32
"Retinal photoreceptors and retinal pigment epithelial (RPE) cells are among the cell types that are sensitive to poisoning with methanol and its toxic metabolite formic acid."( Antioxidants and ocular cell type differences in cytoprotection from formic acid toxicity in vitro.
Burke, JM; Eells, JT; Henry, MM; Skumatz, CM; Treichel, JL, 2004
)
0.32
" These data suggest that antioxidants may serve as 'Abeta targeting' therapies that suppress toxic protein aggregation rather than simply acting as downstream radical scavengers."( Role of glutathione in intracellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity.
Maezawa, I; Milatovic, D; Montine, KS; Montine, TJ; Nghiem, W; Vaisar, T; Woltjer, RL, 2005
)
0.33
"Many adverse drug reactions are caused by the cytochrome P450 (CYP) dependent activation of drugs into reactive metabolites."( An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics.
Grossi, P; Kanter, Rd; Monaci, S; Monshouwer, M; Turlizzi, E; Vignati, L, 2005
)
0.33
" Mrp2 expression not only is important in biliary excretion, but also influences the toxic potential of reactive intermediates by controlling intrahepatic GSH and possibly drug metabolism."( Transport deficient (TR-) hyperbilirubinemic rats are resistant to acetaminophen hepatotoxicity.
Chen, C; Manautou, JE; Silva, VM; Thibodeau, MS, 2005
)
0.33
" BSO treatment depicted an additive toxic effect in CP-treated animals."( Aqueous extract of Trigonella foenum-graecum L. ameliorates additive urotoxicity of buthionine sulfoximine and cyclophosphamide in mice.
Ali, M; Atif, F; Bhatia, K; Kaur, M; Rahman, S; Raisuddin, S; Rehman, H, 2006
)
0.56
" Our results indicate decreased viability in both cell types when treated with MnCl(2) or BSO: Mn was more toxic to SK-N-SH cells, whereas BSO was more toxic to U-87 cells."( Manganese-induced neurotoxicity is differentially enhanced by glutathione depletion in astrocytoma and neuroblastoma cells.
Daniels, CK; Dukhande, VV; Hugus, JJ; Lai, JC; Malthankar-Phatak, GH, 2006
)
0.33
" Was shown relationship between concentration and toxic effect that is nonlinear and characterized with three parts different in induced damages level."( [Mechanisms of 232Th effects on Chlorella vulgaris Beljer and modifications of it's toxic effect with caffeine and buthionine sulfoximine].
Belykh, ES; Evseeva, TI; Geras'kin, SA; Maĭstrenko, TA,
)
0.34
" Cytotoxicity and cell proliferation assays were performed to elucidate the adverse effects of formaldehyde on U2OS cells."( Cytotoxicity of formaldehyde on human osteoblastic cells is related to intracellular glutathione levels.
Chang, YC; Ho, YC; Huang, FM, 2007
)
0.34
"Several adverse health effects, including irritant and allergic contact dermatitis, have been reported among workers who are occupationally exposed to chromium-containing compounds."( Heme-oxygenase 1 gene expression is a marker for hexavalent chromium-induced stress and toxicity in human dermal fibroblasts.
He, Q; Joseph, P; Umbright, C, 2008
)
0.35
" The overexpression of GDNF, regardless of the promoter employed, had no obvious adverse effects on astroglia and the engineered cells stably produced and secreted GDNF for extended periods of time (> or =3 weeks)."( Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity.
Gangaraju, S; Gardaneh, M; Iwasiow, R; Kiuchi, K; Lanthier, P; Ribecco-Lutkiewicz, M; Sandhu, JK; Sikorska, M; Tremblay, R, 2009
)
0.35
"It is well known that antioxidants containing sulfhydryl (-SH) groups are protective against the toxic effects of mercury."( The role of intracellular glutathione in inorganic mercury-induced toxicity in neuroblastoma cells.
Becker, A; Soliman, KF, 2009
)
0.35
" While pre-treatment with GSH-EE did not modify the cytotoxicity or the frequency of ACEG induced by AA, co-treatment with AA and GSH decreased both parameters, rendering the cells less prone to the toxic effects of AA."( Cytotoxicity and chromosomal aberrations induced by acrylamide in V79 cells: role of glutathione modulators.
Fernandes, AS; Gaspar, JF; Martins, C; Martins, V; Oliveira, NG; Pingarilho, M; Rueff, J; Vaz, S, 2009
)
0.35
"Methylmercury (MeHg) is an environmental pollutant known to cause neurobehavioral defects and is especially toxic to the developing brain."( Characterization of antioxidant protection of cultured neural progenitor cells (NPC) against methylmercury (MeHg) toxicity.
Naganuma, A; Nakajo, S; Nakamachi, T; Nakamura, M; Ogawa, T; Shioda, S; Watanabe, J, 2009
)
0.35
" The expression of the CYP2E1 enzyme, which is reported to transform AP to its toxic metabolites, was higher in L-02 than in Hep3B cells."( Acetaminophen-induced cytotoxicity on human normal liver L-02 cells and the protection of antioxidants.
Ji, L; Liang, Q; Min, Y; Sheng, Y; Wang, Z; Xia, Y, 2010
)
0.36
"Cytotoxicity, cell proliferation and collagen synthesis assays were performed to elucidate the toxic effects of CHX on the human osteoblastic cell line U2OS."( Cytotoxicity of chlorhexidine on human osteoblastic cells is related to intracellular glutathione levels.
Chang, YC; Chou, MY; Hu, CC; Lee, SS; Lee, TH, 2010
)
0.36
" Therefore, toxic responses to the reactive metabolites have been expected to be expressed more strongly in a glutathione-depleted condition."( In vitro cytotoxicity assay to evaluate the toxicity of an electrophilic reactive metabolite using glutathione-depleted rat primary cultured hepatocytes.
Fujimoto, K; Kishino, H; Manabe, S; Sanbuissho, A; Yamoto, T, 2010
)
0.36
" These results indicate that low-dose MeHg toxicity may be related to an induction of tau phosphorylation through an oxidative stress-dependent mechanism and that blockade of this pathway may attenuate the toxic effects of MeHg."( Low-dose methylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells.
Agrawal, K; George, W; Mondal, D; Petroni, D; Tsai, J, 2012
)
0.38
"Natural products from plants are expected to play significant roles in creating new, safe and improved chemopreventive and therapeutic antitumor agents."( Selective toxicity of glycyrrhetinic acid against tumorigenic r/m HM-SFME-1 cells is potentially attributed to downregulation of glutathione.
Akitaya, T; Kamiie, K; Kidachi, Y; Noshita, T; Ryoyama, K; Umetsu, H; Yamaguchi, H; Yoshida, K; Yu, T, 2011
)
0.37
" L-Buthionine-SR-sulfoximine treatment exerted an additive toxic effect on the CP-treated animals."( In vivo prevention of bladder urotoxicity: purified hydroxytyrosol ameliorates urotoxic effects of cyclophosphamide and buthionine sulfoximine in mice.
Cherif, M; Elgaaied, AB; Hamden, K; Hamrita, B; Jaouadi, B; Kouidi, S; Medimegh, I; Messai, Y; Ouerhani, S; Rouissi, K, 2011
)
0.58
" In conclusion, MDMA catechol metabolites promote differential toxic effects to differentiated dopaminergic human SH-SY5Y cells."( Neurotoxicity of "ecstasy" and its metabolites in human dopaminergic differentiated SH-SY5Y cells.
Bastos, ML; Branco, PS; Capela, JP; Carvalho, F; Costa, VM; Fernandes, E; Ferreira, LM; Ferreira, PS; Meisel, A; Nogueira, TB, 2013
)
0.39
" Mechanisms other than glutathione depletion and ROS formation seem to be of importance for the toxic effect of HEMA on lung epithelial cells."( Cell toxicity of 2-hydroxyethyl methacrylate (HEMA): the role of oxidative stress.
Ansteinsson, V; Morisbak, E; Samuelsen, JT, 2015
)
0.42
" Cytotoxicity parameters, such as [3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT), neutral red uptake (NRU), and lactate dehydrogenase (LDH) release suggested that cobalt NPs were toxic to MCF-7 cells in a dose-dependent manner (50-200μg/ml)."( Nanotoxicity of cobalt induced by oxidant generation and glutathione depletion in MCF-7 cells.
Ahamed, M; Akhtar, MJ; Alhadlaq, HA; Alshamsan, A, 2017
)
0.46
"Exposure to chemicals might be toxic to the developing brain."( Comparison of neurons derived from mouse P19, rat PC12 and human SH-SY5Y cells in the assessment of chemical- and toxin-induced neurotoxicity.
Jacobsson, SOP; Karlsson, J; Popova, D, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" Diethylmaleate pretreatment decreased the total clearance and increased the half-life of acetaminophen."( Role of glutathione turnover in drug sulfation: differential effects of diethylmaleate and buthionine sulfoximine on the pharmacokinetics of acetaminophen in the rat.
Galinsky, RE, 1986
)
0.49
"The development of time-dependent pharmacodynamic models in cancer chemotherapy has been extremely limited."( Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Brennan, J; Gallo, JM; Halbherr, T; Hamilton, TC; Laub, PB; O'Dwyer, PJ; Ozols, RF, 1995
)
0.49
" Values for steady-state volume of distribution and renal clearance were similar for both isomers, but total clearance, nonrenal clearance, and half-life were approximately 25% different, with the R-(inactive) isomer being eliminated faster (higher clearance and shorter half-life) than the S- (active) isomer."( Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
Brennan, JM; Hamilton, TC; Lacreta, FP; O'Dwyer, PJ; Ozols, RF,
)
0.13
"To develop dosing criteria for the use of L-buthionine-S-sulfoximine (active diastereoisomer) as a glutathione depletor in the clinic, using a pharmacodynamic and pharmacokinetic in vitro-in vivo approach."( Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine.
Bump, EA; Coleman, CN; Griffith, OW; Hurwitz, SJ; Lai, LL; Malaker, K; Riese, N, 1994
)
0.54
"Nanoparticles degradable upon external stimuli combine pharmacokinetic features of both small molecules as well as large nanoparticles."( Impact of Glutathione Modulation on Stability and Pharmacokinetic Profile of Redox-Sensitive Nanogels.
Drude, N; Königs, H; Möller, M; Morgenroth, A; Mottaghy, FM; Roller, M; Singh, S; Winz, OH, 2018
)
0.48

Compound-Compound Interactions

The glutathione inhibitor drugs, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and buthionine sulfoximine (BSO) were tested in vitro in order to assess their cytotoxic effectiveness when combined with an enzyme immunotoxin.

ExcerptReferenceRelevance
" BSO demonstrated in vivo antitumor activity in B16 melanoma-bearing mice prolonging survival by 29% and in combination with 3,4-DHBA resulted in a slight (48% versus 38%) increase in life span as compared to 3,4-DHBA alone."( Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
FitzGerald, GB; Prezioso, JA; Wick, MM, 1992
)
0.59
" SHDAAs, including doxorubicin (DOX), cyclophosphamide (CTX), carmustine (BCNU) and melphalan (L-PAM) were then combined with L-BSO in mice bearing P388, MOPC-315 or colon 38 tumors."( Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Dorr, RT; Soble, MJ,
)
0.4
"The radiosensitizing effects of misonidazole (MISO) in combination with D,L-buthionine-S, R-sulfoximine (BSO), an inhibitor of glutathione (GSH) biosynthesis, were studied in NFSa tumors of C3H/He mice."( Radiosensitizing effect of misonidazole in combination with an inhibitor of glutathione synthesis in murine tumors.
Abe, M; Komuro, C; Nishidai, T; Ono, K; Shibamoto, Y; Takahashi, M; Tsutsui, K, 1986
)
0.27
" We determined the cytotoxicity of BSO (dose range 0-1000 microM) alone and in combination with L-PAM (dose range 0-0 microM) in a panel of 18 human neuroblastoma cell lines."( Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines.
Anderson, CP; Chan, W; Forman, HJ; Lui, RM; Park, CK; Reynolds, CP; Tian, L; Tsai, J, 1997
)
0.3
" We investigated the reversing effect of PAK-104P in C-A120 cells in combination with buthionine sulfoximine (BSO), another MDR-reversing agent with a different reversing mechanism."( Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P.
Aikou, T; Akiyama, S; Chen, ZS; Chuman, Y; Furukawa, T; Haraguchi, M; Niwa, K; Seto, K; Sumizawa, T; Tani, A; Yamada, K, 1998
)
0.76
"BSO was administered in combination with Photofrin as the photosensitizer in order to promote PDT induced cell damage."( Photodynamic therapy using Photofrin in combination with buthionine sulfoximine (BSO) to treat 9L gliosarcoma in rat brain.
Belcuig, M; Chopp, M; Grenier, J; Jiang, F; Li, Y; Lilge, L; Singh, G, 1998
)
0.55
"E-ras 20 tumorigenic malignant cells and CV-1 non-tumorigenic cells were treated with a drug combination of 4-iodo-3-nitrobenzamide (INO(2)BA) and buthionine sulfoximine (BSO)."( Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease.
Bauer, PI; Buki, KG; Comstock, JA; Hakam, A; Kirsten, E; Kun, E; Mendeleyeva, J, 2002
)
0.75
" Therefore, we hypothesize that PDT in combination with Buthionine Sulfoximine (BSO), an agent which lowers cellular glutathione, can significantly enhance destruction of U87 and U251n tumour cells."( Photodynamic therapy with photofrin in combination with Buthionine Sulfoximine (BSO) of human glioma in the nude rat.
Chopp, M; Espiritu, M; Jiang, F; Katakowski, M; Robin, AM; Singh, G; Tong, L, 2003
)
0.81
" The current work tests the hypothesis that 2-deoxy-d-glucose (2DG) combined with cisplatin [cis-diamminedichloroplatinum(II)] can enhance cytotoxicity in human head and neck cancer cells (FaDu) by mechanisms involving oxidative stress."( 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells.
Ahmad, IM; Dornfeld, KJ; Mattson, DM; Simons, AL; Spitz, DR, 2007
)
0.34
"0 micromol/L) alone or combined with BSO (100 micromol/L)."( [The effect of arsenic trioxide (As2O3) combined with BSO on K562/ADM cell and its mechanisms].
Ma, LM; Qiao, ZH; Wang, HW; Wang, T; Yang, LH; Zhang, HP, 2007
)
0.34
"To investigate the apoptosis-inhancing effect of the combination of arsenic trioxide (As2O3 ) and buthionine sulfoximine (BSO) on multidrug-resistant human leukemic K562/ADM cells, to compare the effect of As2O3 alone and As2O3 combined with BSO and As2O3 alone, and to determine the effect of intracellular GSH content on this treatment."( [Arsenic trioxide combined with buthionine sulfoximine enhances apoptosis in multidrug-resistant human leukemia K562/ADM cells in vitro].
Ma, LM; Qiao, ZH; Wang, HW; Wang, T; Yang, LH; Zhang, HP, 2008
)
0.85
" These findings provide a biochemical rationale for evaluating agents that induce mitochondrial dysfunction in combination with chemotherapy and inhibitors of glutathione metabolism in head and neck cancer."( Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism.
Ahmad, IM; Aykin-Burns, N; Dayal, D; Dornfeld, KJ; Li, L; Mattson, DM; Orcutt, KP; Parsons, AD; Simons, AL; Spitz, DR, 2009
)
0.35
", l-buthionine-S,R-sulfoximine, BSO) metabolism were utilized in combination with a chemotherapeutic agent, paclitaxel (PTX), thought to induce oxidative stress, to treat breast cancer cells."( Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress.
Aykin-Burns, N; Coleman, MC; Hadzic, T; Jacobson, GM; Leick, K; Spitz, DR; Zhu, Y, 2010
)
0.36
"To evaluate BSO-mediated glutathione (GSH) depletion in combination with L-PAM for children with recurrent or refractory high-risk neuroblastoma (NB) as a means to enhance alkylator sensitivity."( Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
Anderson, CP; Bailey, HH; Groshen, S; Hasenauer, B; Maris, JM; Matthay, KK; Neglia, JP; Perentesis, JP; Reynolds, CP; Seeger, RC; Villablanca, JG, 2015
)
0.65

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability of BSO, based on plasma BSO levels, was extremely low."( Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
Grieshaber, CK; Liao, JT; Page, JG; Smith, AC; Wientjes, MG, 1989
)
0.6
" In this study, an attempt was made to correlate cellular bioavailability and metabolism of cysteine derivatives with protection against UV-induced reactive intermediates."( Cysteine derivatives protect against UV-induced reactive intermediates in human keratinocytes: the role of glutathione synthesis.
Beijersbergen van Henegouwen, GM; Steenvoorden, DP, 1997
)
0.3
" (d) Our data therefore indicate superior endothelial function in the obese relative to the lean Zucker rat, reflected by a greater regulation of vasoconstrictor reactivity by basal NO, while the regulation of NO bioavailability by superoxide anion is similar."( Investigation of basal endothelial function in the obese Zucker rat in vitro.
Anggård, EE; Carrier, MJ; Laight, DW, 2000
)
0.31
" Thus, enhanced PE contraction, blunted endothelium-dependent relaxation, and adaptations in nitric oxide bioavailability pathways provide the first evidence of chronic, in vivo BSO-induced, oxidative stress-mediated direct effects on the vasomotor function of arteries."( Glutathione depletion in vivo enhances contraction and attenuates endothelium-dependent relaxation of isolated rat aorta.
Denniss, SG; Ford, RJ; Graham, DA; Quadrilatero, J; Rush, JW, 2006
)
0.33
" The efflux of Mrp2, not P-gp, in the intestinal of the rats may be one of the reasons that lead to the low oral bioavailability of scutellarin."( Mrp2-related efflux of scutellarin in the intestinal absorption in rats.
Cao, F; Guo, J; Ping, Q; Zhang, H, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Rat embryos were cultured in serum from rats pretreated with two GSH depleters (phorone and buthionine sulfoximine) and subsequently dosed with PCZ. To test whether inhibition of protein synthesis was related to GSH depletion, groups of animals were doses with the alpha, beta-unsaturated carbonyl phorone (diisopropylidenacetone) or the specific inhibitor of GSH synthesis, buthionse sulfoxin (BSO)

ExcerptRelevanceReference
" Tumor GSH levels were decreased with all BSO dosing regimens tested."( The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine.
Bigner, DD; Brizel, DM; Friedman, HS; Griffith, OW; Halperin, EC; Honore, G; Sontag, MR, 1992
)
0.49
" Dose-response curves were obtained using cells irradiated in the absence or presence of DEM/BSO, which decreased GSH levels by 90-95%."( Depletion of glutathione after gamma irradiation modifies survival.
Eisert, DR; Freeman, ML; Meredith, MJ; Saunders, EL, 1991
)
0.28
" We successfully employed ESR to detect the formation of the 5,5-dimethyl-1-pyrroline-N-oxide (DMPO)/hemoglobin thiyl free radical adduct in the blood of rats dosed with DMPO and tert-butyl hydroperoxide, cumene hydroperoxide, ethyl hydrogen peroxide, 2-butanone hydroperoxide, 15(S)-hydroperoxy-5,8,11,13-eicosatetraenoic acid, or hydrogen peroxide."( In vivo thiyl free radical formation from hemoglobin following administration of hydroperoxides.
Jordan, SJ; Kennedy, CH; Maples, KR; Mason, RP, 1990
)
0.28
" In addition, the hepatic MT content was increased by the administration of cysteine in a dose-response manner."( On the metallothionein, glutathione and cysteine relationship in rat liver.
Armario, A; Garvey, JS; Hidalgo, J, 1990
)
0.28
" with 250 mg/kg of phorone, a GSH depleting agent and/or 200 mg/kg of buthionine sulfoximine (BSO, an inhibitor of GSH biosynthesis) 4 hours before dosing with 5-FU."( Effects of phorone and/or buthionine sulfoximine on teratogenicity of 5-fluorouracil in mice.
Deguchi, T; Mataki, Y; Naya, M; Takahira, H; Yasuda, M, 1990
)
0.81
"A melphalan-resistant human rhabdomyosarcoma xenograft, TE-671 MR, was established in athymic mice by serial melphalan treatment of the parent xenograft, TE-671, at the 10% lethal dosage (LD10); significant resistance was evident after ten passages of the tumor."( Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
Bigner, DD; Bigner, SH; Colvin, OM; Elion, GB; Friedman, HS; Griffith, OW; Horton, JK; Lilley, E; Rosenberg, MC, 1989
)
0.48
" with TCE in a dosage of 125-1000 mg/kg in sesame oil."( Lipid peroxidation: a possible mechanism of trichloroethylene-induced nephrotoxicity.
Beuter, W; Cojocel, C; Mayer, D; Müller, W, 1989
)
0.28
" These experiments were used to establish a repeated dosing protocol for more prolonged GSH depletion."( The pulmonary effects of buthionine sulfoximine treatment and glutathione depletion in rats.
Cihla, HP; Coursin, DB, 1988
)
0.58
" In the liver of the DL-buthionine-(S,R)-sulfoximine (BSO)-treated rats dosed with m-DCB, both of 2,4- and 3,5-DCPSO2Mes were present at significantly lower concentrations than in non-BSO-treated rats."( Contribution of methylsulfonyl metabolites of m-dichlorobenzene to the heme metabolic enzyme induction by the parent compound in rat liver.
Kato, Y; Kimura, R; Kogure, T; Sato, M, 1988
)
0.27
" Further studies should evaluate different dosing intervals to take advantage of the slower rate of GSH replenishment observed in normal tissues compared to solid tumor cells (Colon 38) in vivo."( Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Dorr, RT; Soble, MJ,
)
0.4
" Tumor GSH could be maintained at a level 8% of control by daily dosing with BSO for 3 days."( Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono, K; Shrieve, DC, 1987
)
0.55
" After a 4-hr pretreatment with DL-buthionine-SR-sulfoximine (BSO), a specific inhibitor of GSH synthesis, male Sprague-Dawley rats were dosed with radiolabeled DMN (250 micrograms/kg)."( Effect of glutathione modulation using buthionine sulfoximine on DNA methylation by dimethylnitrosamine in the rat.
Jensen, DE; Magee, PN; Tacchi, AM, 1987
)
0.54
" Multiple BSO dosing at 16 h intervals allowed the liver to recover between doses, but the recovery in the kidney, lung and bone marrow was only partial and no recovery was seen in the heart."( Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine.
Allalunis-Turner, MJ; Lee, FY; Siemann, DW, 1987
)
0.52
" Kidneys from hamsters treated with the GSH synthesis inhibitor L-buthionine-(S,R)-sulfoximine at a dosage of 1 mmol/kg body wt for 2 hr had 45% of the NP-SH content as compared with kidneys of saline-treated controls."( Glutathione protection against irreversible binding of diethylstilbestrol in the hamster renal cortex.
Adams, SP; Notides, AC, 1987
)
0.27
" To test whether inhibition of protein synthesis was related to GSH depletion, groups of animals were dosed with the alpha, beta-unsaturated carbonyl phorone (diisopropylidenacetone) or the specific inhibitor of GSH synthesis, buthionine sulfoximine (BSO)."( Effect of diethylmaleate and other glutathione depletors on protein synthesis.
Costa, LG; Murphy, SD, 1986
)
0.46
" Different dosing regimens of BSO were found to potentiate L-PAM toxicity in a manner that depended upon the degree of GSH depletion."( Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Ahmad, S; Greene, K; Kramer, RA; Vistica, DT, 1987
)
0.5
" A series of human ovarian cancer cell lines have been developed in which dose-response relationships to standard anticancer drugs have been determined, and the patterns of cross-resistance between these drugs and irradiation have been established."( Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
Behrens, BC; Grotzinger, KR; Hamilton, TC; Kinsella, TJ; Louie, KG; McKoy, WM; Ozols, RF; Winker, MA, 1985
)
0.47
" Time-dependent pharmacodynamic models are seen as a powerful means to design dosing regimens and to provide a mathematical platform for mechanistic based models."( Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Brennan, J; Gallo, JM; Halbherr, T; Hamilton, TC; Laub, PB; O'Dwyer, PJ; Ozols, RF, 1995
)
0.49
" Therefore, in a second set of experiments, rat embryos were cultured in serum from rats pretreated with two GSH depleters (phorone and buthionine sulfoximine) and subsequently dosed with PCZ."( Profile of procarbazine-induced embryotoxicity in an embryo hepatocyte co-culture system and after in utero glutathione depletion.
Andrews, JE; Ebron-McCoy, MT; Kavlock, RJ; Nichols, HP, 1995
)
0.49
" A dose-response curve showed that a maximum depletion (86%) of GSH in the mother's liver was produced by the 6 mmol/kg dose of BSO."( The effect of in utero administration of buthionine sulfoximine on rat development.
Contreras, R; Ott, S; Reyes, E; Robinson, B, 1995
)
0.56
"To develop dosing criteria for the use of L-buthionine-S-sulfoximine (active diastereoisomer) as a glutathione depletor in the clinic, using a pharmacodynamic and pharmacokinetic in vitro-in vivo approach."( Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine.
Bump, EA; Coleman, CN; Griffith, OW; Hurwitz, SJ; Lai, LL; Malaker, K; Riese, N, 1994
)
0.54
" However, glucose protected the cells from killing induced by milder exposure (1 mumol/10(7) cells) to the oxidant causing a shift in the dose-response curve."( The role of glucose in cellular defences against cytotoxicity of hydrogen peroxide in Chinese hamster ovary cells.
Averill-Bates, DA; Przybytkowski, E, 1994
)
0.29
" At low, therapeutically relevant radiation doses, where 2-nitroimidazoles are less efficient sensitizers, the preincubation effect may be even more important, but thiol depletion still minimizes its impact in this region of the dose-response curve."( Enhanced radiation-sensitivity by preincubation with nitroimidazoles: effect of glutathione depletion.
Koch, CJ; Skov, KA, 1994
)
0.29
" Maximal GSH depletion (40% of baseline values, absolute values 200 to 250 ng/10(6) PBLs) was noted after the sixth BSO dose; extended BSO dosing schedules beyond six total BSO doses did not further deplete GSH."( Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Alberti, D; Arzoomanian, RZ; Bailey, HH; Mulcahy, RT; Pomplun, M; Spriggs, DR; Tombes, MB; Tutsch, KD; Wilding, G, 1994
)
0.56
"The formation of paramagnetic chromium in the liver of male mice dosed with K2Cr2O7 (10, 20, and 40 mg Cr/kg) by a single ip injection was investigated by electron spin resonance (ESR) spectrometry."( Formation of paramagnetic chromium in liver of mice treated with dichromate (VI).
Furukawa, Y; Sugiyama, M; Susa, N; Ueno, S, 1995
)
0.29
" We measured plasma concentrations of R- and S-BSO by high-performance liquid chromatography (HPLC) in 22 patients throughout the dosing period."( Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
Bookman, MA; Brennan, J; Comis, RL; Gallo, JM; Halbherr, T; Hamilton, TC; Hoffman, J; Kilpatrick, D; LaCreta, FP; O'Dwyer, PJ; Ozols, RF; Young, RC, 1996
)
0.63
" Part 1 of the study established a dose-response curve and the temporal pattern of GSH loss and recovery in the substantia nigra and striatum following acute BSO treatment."( Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons.
Andersen, JK; Hamill, RW; Harnish, P; Hom, DG; Lee, FY; McNeill, TH; Mo, JQ, 1996
)
0.7
" After oral dosing with BDCM, the BSO-pretreated animals had greatly increased levels of serum indicators of hepatotoxicity and serum and urinary indicators of nephrotoxicity compared to those in animals dosed solely with BDCM."( Protective effects of glutathione on bromodichloromethane in vivo toxicity and in vitro macromolecular binding in Fischer 344 rats.
Gao, P; Pegram, RA; Thornton-Manning, JR, 1996
)
0.29
" The effects of BSO on the alcohol dose-response curves (body weights, brain weights, and litter number) were then determined to ascertain if a depletion in GSH potentiated the effects of alcohol."( Effects of buthionine sulfoximine on the outcome of the in utero administration of alcohol on fetal development.
Ott, S; Reyes, E, 1996
)
0.68
"To determine the dose-response relationship, BSO at doses of 10 to 100 mg/ml, in platelet-rich plasma, was applied for 7 days to rat femoral arteries in vivo."( Reduction of intracellular glutathione levels produces sustained arterial narrowing.
Gajdusek, C; London, S; Mayberg, MR; Zhou, D, 1996
)
0.29
" Exposure of the GM2E1 cells to NDMA for 4 days caused severe decreases in cell viability, as determined by crystal violet uptake, and showed a sigmoidal dose-response curve with a median lethal dose of 17 microM."( Heterologous expression of rat P450 2E1 in a mammalian cell line: in situ metabolism and cytotoxicity of N-nitrosodimethylamine.
Hollenberg, PF; Lin, HL; Roberts, ES, 1998
)
0.3
" The antitumor activity of CDDP as assessed by tumor weight change and tumor growth delay was weak in this tumor model irrespective of prior BSO administration or CDDP dosing time."( Pharmacological modulation of cisplatin toxicity rhythms with buthionine sulfoximine in mice bearing pancreatic adenocarcinoma (PO3).
Filipski, E; Lévi, F; Li, XM, 1998
)
0.54
" Dosing 1-OHP at these times achieved intermediate."( Modulation of nonprotein sulphydryl compounds rhythm with buthionine sulphoximine: relationship with oxaliplatin toxicity in mice.
Filipski, E; Lemaigre, G; Lévi, F; Li, XM; Metzger, G, 1998
)
0.3
" At the highest dosage (40 mM) the b-wave was significantly reduced within 2 min of injection."( Inhibition of Müller cell glutamine synthetase rapidly impairs the retinal response to light.
Barnett, NL; Pow, DV; Robinson, SR, 2000
)
0.31
"Heterogeneous RT dose-response relationships in the in vitro assay were demonstrated."( Development of an in vitro chemo-radiation response assay for cervical carcinoma.
Burger, RA; Fruehauf, JP; Monk, BJ; Parker, R; Radany, EH; Redpath, L, 2002
)
0.31
" Both oxidative stress and apoptosis exhibited a dose-response relationship with CSE concentrations."( Cigarette smoke extract induces oxidative stress and apoptosis in human lung fibroblasts.
Barale, R; Carnevali, S; Celi, A; Cipollini, M; Giuntini, C; Longoni, B; Paggiaro, P; Petruzzelli, S; Scatena, F; Vanacore, R, 2003
)
0.32
" Treatment with BSO produced dose-dependent decreases in total GSH level, Fe3+-reducing ability (FRAP assay), Cu2+-reducing ability (Antioxidant Potential, AOP assay), and ABTS free radical scavenging ability (ABTS assay) of the cells, but the sensitivity of these indicators to dosage varied considerably."( The responses of Ht22 cells to oxidative stress induced by buthionine sulfoximine (BSO).
Berry, MJ; Chen, J; Small-Howard, A; Yin, A, 2005
)
0.57
" BSO shifted the phenylephrine (PE) dose-response curve to the left (p=0."( Glutathione depletion in vivo enhances contraction and attenuates endothelium-dependent relaxation of isolated rat aorta.
Denniss, SG; Ford, RJ; Graham, DA; Quadrilatero, J; Rush, JW, 2006
)
0.33
" Cytotoxicity of deferoxamine for neuroblastoma cell lines measured by the DIMSCAN assay achieved dose-response curves similar to data obtained by manual trypan blue counts or colony formation in soft agar but with a wider dynamic range."( A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.
Frgala, T; Kalous, O; Proffitt, RT; Reynolds, CP, 2007
)
0.34
" Administration of radiolabeled AQ in combination with BSO exhibited significantly higher covalent binding to mice liver proteins than that observed after sole dosing of radiolabeled AQ."( Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice.
Aoki, T; Atsumi, R; Itokawa, K; Iwasaki, M; Izumi, T; Okazaki, O; Ono, C; Shimizu, S; Sudo, K, 2009
)
0.35
"Though, oxidative stress has been implicated in silica nanoparticles induced toxicity both in vitro and in vivo, but no similarities exist regarding dose-response relationship."( Nanotoxicity of pure silica mediated through oxidant generation rather than glutathione depletion in human lung epithelial cells.
Ahamed, M; Ahmad, I; Akhtar, MJ; Ashquin, M; Kumar, S; Patil, G; Siddiqui, H, 2010
)
0.36
" Administration of radio-labeled TIC in combination with BSO resulted in significantly higher covalent binding to rat liver proteins than that observed after sole dosing of radio-labeled TIC."( Ticlopidine-induced hepatotoxicity in a GSH-depleted rat model.
Atsumi, R; Izumi, T; Nakazawa, T; Okazaki, O; Saji, H; Shimizu, S; Sudo, K, 2011
)
0.37
" After 24h, cells were dosed with the IL-6-like cytokine, leukemia inhibitory factor (LIF)."( Depletion of cellular glutathione modulates LIF-induced JAK1-STAT3 signaling in cardiac myocytes.
Aon, MA; Booz, GW; Duhé, RJ; Kurdi, M; Paolocci, N; Sivakumaran, V, 2012
)
0.38
" Each sample was used for glutathione ad lipid peroxidation level dosage and for evaluating the expression of heme oxygenase both after a single subcutaneous administration of BSO and without treatment."( Neuroprotective effects of a glutathione depletor in rat post-ischemic reperfusion brain damage.
Acquaviva, R; Di Giacomo, C; Santangelo, R; Sorrenti, V; Volti, GL, 2015
)
0.42
" Finally, after treatment with L-buthionine-S,R-sulfoxinine, an inhibitor of glutathione synthesis, TA-induced hepatic necrosis was enhanced and hepatic TBARS contents increased after TA dosing in HFD mice."( Hepatic glutathione contributes to attenuation of thioacetamide-induced hepatic necrosis due to suppression of oxidative stress in diet-induced obese mice.
Kai, K; Makino, T; Matsuoka, M; Shirai, M; Takasaki, W; Teranishi, M, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 6.3.2.2 (glutamate--cysteine ligase) inhibitorAn acid--amino-acid ligase inhibitor that inhibits the action of a glutamate--cysteine ligase (EC 6.3.2.2)
ferroptosis inducerAny substance that induces or promotes ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
ferroptosis inducerAny substance that induces or promotes ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
EC 6.3.2.2 (glutamate--cysteine ligase) inhibitorAn acid--amino-acid ligase inhibitor that inhibits the action of a glutamate--cysteine ligase (EC 6.3.2.2)
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
homocysteines
sulfoximideCompounds having the structure RS(=O)=NR.
diastereoisomeric mixtureA mixture composed of two or more diastereoisomers (stereoisomers not related as mirror images).
2-amino-4-(S-butylsulfonimidoyl)butanoic acidA non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
6-methoxymellein biosynthesis022

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
EWS/FLI fusion proteinHomo sapiens (human)Potency14.81800.001310.157742.8575AID1259252
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency21.19230.035520.977089.1251AID504332
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency17.78280.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
thioredoxin reductaseRattus norvegicus (Norway rat)Potency33.58750.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency9.19620.004110.890331.5287AID493107
GLS proteinHomo sapiens (human)Potency31.62280.35487.935539.8107AID624146
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency21.13170.001530.607315,848.9004AID1224820
arylsulfatase AHomo sapiens (human)Potency0.00601.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00500.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency5.62340.006026.168889.1251AID488953
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency6.74560.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (102)

Assay IDTitleYearJournalArticle
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1151829Induction of eumelanogenesis assessed as mushroom tyrosinase-mediated simulation of eumelanogenesis by measuring oxidation of L-DOPA at 4.5 to 184.4 mM after 48 hrs by Vis-spectrophotometer analysis in absence of glutathione and presence of H2O22014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Buthionine sulfoximine diverts the melanogenesis pathway toward the production of more soluble and degradable pigments.
AID1151831Induction of pheomelanogenesis assessed as mushroom tyrosinase-mediated simulation of pheomelanogenesis by measuring oxidation of L-DOPA at 4.5 to 184.4 mM after 48 hrs by Vis-spectrophotometer analysis in presence of 0.65 to 3.2 mM of glutathione and H2O2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Buthionine sulfoximine diverts the melanogenesis pathway toward the production of more soluble and degradable pigments.
AID1726485Induction of ROS generation in human MDA-MB-231 cells assessed as increase in ROS level at 1 mM incubated for 12 hrs by DAPI staining based assay2021RSC medicinal chemistry, Apr-28, Volume: 12, Issue:4
Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).
AID1726499Synergistic cytotoxicity against human MDA-MB-231 cells assessed as restoration of oxidative stress measured after 72 hrs in presence of YM1552021RSC medicinal chemistry, Apr-28, Volume: 12, Issue:4
Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).
AID1151828Induction of eumelanogenesis assessed as mushroom tyrosinase-mediated simulation of eumelanogenesis by measuring oxidation of L-DOPA at 4.5 to 184.4 mM after 48 hrs by Vis-spectrophotometer analysis in absence of glutathione2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Buthionine sulfoximine diverts the melanogenesis pathway toward the production of more soluble and degradable pigments.
AID1726500Synergistic cytotoxicity against human BT-20 cells assessed as restoration of oxidative stress measured after 72 hrs in presence of YM1552021RSC medicinal chemistry, Apr-28, Volume: 12, Issue:4
Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).
AID1726481Inhibition of survivin in human BT-20 cells assessed as reduction in survivin mRNA expression measured after 72 hrs by qPCR analysis2021RSC medicinal chemistry, Apr-28, Volume: 12, Issue:4
Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).
AID1726472Cytotoxicity against human MCF-10A cells at 200 uM2021RSC medicinal chemistry, Apr-28, Volume: 12, Issue:4
Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).
AID1726501Synergistic cytotoxicity against human MDA-MB-453 cells assessed as restoration of oxidative stress measured after 72 hrs in presence of YM1552021RSC medicinal chemistry, Apr-28, Volume: 12, Issue:4
Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).
AID1726480Inhibition of survivin in human MDA-MB-231 cells assessed as reduction in survivin mRNA expression measured after 72 hrs by qPCR analysis2021RSC medicinal chemistry, Apr-28, Volume: 12, Issue:4
Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).
AID1723840Inhibition glutathione synthesis in human MIA PaCa-2 cells at 1 to 2 uM measured after 2 to 4 hrs by GSH/GSSG-glo assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
A Novel Redox Modulator Induces a GPX4-Mediated Cell Death That Is Dependent on Iron and Reactive Oxygen Species.
AID1151830Induction of pheomelanogenesis assessed as mushroom tyrosinase-mediated simulation of pheomelanogenesis by measuring oxidation of L-DOPA at 4.5 to 184.4 mM after 48 hrs by Vis-spectrophotometer analysis in presence of 0.65 to 3.2 mM of glutathione2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Buthionine sulfoximine diverts the melanogenesis pathway toward the production of more soluble and degradable pigments.
AID1151832Inhibition of mushroom tyrosinase-mediated simulation of pheomelanogenesis assessed as oxidation of L-DOPA at 4.5 to 184.4 mM after 48 hrs by Vis-spectrophotometer analysis in presence of 16.3 to 81.3 mM of glutathione2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Buthionine sulfoximine diverts the melanogenesis pathway toward the production of more soluble and degradable pigments.
AID1726482Inhibition of survivin in human MDA-MB-453 cells assessed as reduction in survivin mRNA expression measured after 72 hrs by qPCR analysis2021RSC medicinal chemistry, Apr-28, Volume: 12, Issue:4
Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).
AID1726488Downregulation of survivin protein expression in human MDA-MB-231 cells at 1 mM incubated for 72 hrs by Western blot analysis2021RSC medicinal chemistry, Apr-28, Volume: 12, Issue:4
Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID520479Antitrypanosomal activity against Trypanosoma cruzi clone Dm28c metacyclic trypomastigotes infected in BALB/c mouse assessed as increase in survival rate at 2.5 mg/kg/day, ip measured after 20 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
AID520473Antitrypanosomal activity against Trypanosoma cruzi clone Dm28c metacyclic trypomastigotes infected in mouse assessed as decrease in heart parasite burden at 220 mg/kg/day, ip measured after 20 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
AID328610Reduction of glutathione synthesis in human MCF7 cells at 25 uM after 25 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID520474Toxicity in BALB/c mouse at 220 mg/kg/day, ip measured after 20 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
AID520478Antitrypanosomal activity against Trypanosoma cruzi clone Dm28c metacyclic trypomastigotes infected in BALB/c mouse assessed as increase in survival rate at 10 mg/kg/day, ip measured after 20 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
AID696028Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs in presence of tiopronin by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID520475Antitrypanosomal activity against Trypanosoma cruzi clone Dm28c metacyclic trypomastigotes infected in BALB/c mouse assessed as increase in survival rate at 30 mg/kg/day, ip measured after 20 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID520476Antitrypanosomal activity against Trypanosoma cruzi clone Dm28c metacyclic trypomastigotes infected in mouse assessed as decrease in heart parasitemia at 30 mg/kg/day, ip measured after 20 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID520358Antitrypanosomal activity against Trypanosoma cruzi clone Dm28c metacyclic trypomastigotes infected in BALB/c mouse assessed as increase in survival rate at 220 mg/kg/day, ip measured after 20 days (Rvb = 25%)2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
AID520472Antitrypanosomal activity against Trypanosoma cruzi clone Dm28c metacyclic trypomastigotes infected in mouse assessed as decrease in heart parasitemia at 220 mg/kg/day, ip measured after 20 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
AID520477Antitrypanosomal activity against Trypanosoma cruzi clone Dm28c metacyclic trypomastigotes infected in mouse assessed as decrease in heart parasite burden at 30 mg/kg/day, ip measured after 20 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1196845Reduction of cellular GSH level in human HT-29 cells after 24 hrs by firefly luciferase assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Design, synthesis, and biological evaluation of sulfonyl acrylonitriles as novel inhibitors of cancer metastasis and spread.
AID1196846Cytotoxicity against human HT-29 cells co-cultured with human mesothelial cells at 50 to 200 uM preincubated for 24 hrs followed by co-culturing measured after 4 hrs by firefly luciferase assay relative to control2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Design, synthesis, and biological evaluation of sulfonyl acrylonitriles as novel inhibitors of cancer metastasis and spread.
AID1307956Reduction in in glutathione level in NHBE cells at 3 mM incubated for 18 hrs by thiostar dye based fluorescence assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,389)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990310 (12.98)18.7374
1990's900 (37.67)18.2507
2000's705 (29.51)29.6817
2010's409 (17.12)24.3611
2020's65 (2.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.35 (24.57)
Research Supply Index7.81 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index50.43 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (0.33%)5.53%
Trials0 (0.00%)5.53%
Reviews31 (1.26%)6.00%
Reviews0 (0.00%)6.00%
Case Studies2 (0.08%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other2,419 (98.33%)84.16%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-Label, Multicenter, Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic Buthionine Sulfoximine (BSO) in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advan [NCT00661336]Phase 10 participants (Actual)Interventional2008-04-30Withdrawn(stopped due to The study was withdrawn due to lack of patients.)
PILOT STUDY OF BUTHIONINE SULFOXIMINE (BSO) IN COMBINATION WITH MELPHALAN FOR HIGH RISK NEUROBLASTOMA PATIENTS [NCT00002730]Phase 10 participants Interventional1996-06-30Completed
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112) [NCT00005835]Phase 131 participants (Actual)Interventional2001-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]